FOLFOXIRI plus a is an ideal regimen for conversion in the treatment of advanced/recurrent colorectal cancer

As treatment for advanced/recurrent colorectal cancer (ARCC), the introduction of doublet chemotherapy, represented by FOLFOX/FOLFIRI, and molecular-targeting agents, such as anti-VEGF antibody and anti-EGFR antibody, has given ARCC patients a more than three years' survival. Triplet chemotherapy, such as FOLFOXIRI+a, has already been used in daily practice. These regimens with powerful anti-tumor effects have enabled conversion, giving patients a longer survival than those without conversion. Therefore, we explored the ideal regimen for conversion, focusing on FOLFOXIRI+a.